Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat

Neuroscience

Volumn 76, Issue 2, 1997, Pages 345-354

  Kaur, S ^a   Starr, M S ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AMPA; Glutamate; NMDA; Rat; Reserpine; Substantia nigra pars reticulata

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 5 PHOSPHONOVALERIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DIZOCILPINE; ELIPRODIL; GLUTAMATE RECEPTOR ANTAGONIST; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RESERPINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; BRAIN CHEMISTRY; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS; MALE; MOTOR ACTIVITY; NEOSTRIATUM; NEUROTRANSMITTER UPTAKE INHIBITORS; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RESERPINE; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA;

EID: 0031023261     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00407-1     Document Type: Article

References (64)

1. Albin R. L., Aldridge J. W., Young A. B. and Gilman S. (1989) Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res. 491, 185-188.
2. Albin R. L., Makowiec R. L., Hollingsworth Z. R., Dure L. S., Penney J. B. and Young A. B. (1992) Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 46, 35-48.
3. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
4. Alkhatib I., Karadag H. C. and Ulugol A. (1995) The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats. Pharmac. Biochem. Behav. 52, 723-730.
5. Bergman H., Wichmann T. and DeLong M. R. (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249, 1436-1438.
6. Brooks S., Kaur S. and Starr B. S. and Starr M. S. (1996) Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease? J. neural Transm., 103, 737-748.
7. Brotchie J. M., Mitchell I. J., Sambrook M. A. and Crossman A. R. (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6, 133-138.
8. Carlsson M. L. (1993) Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J. neural Transm. 75, 221-226.
9. Carroll C. B., Holloway V., Brotchie J. M. and Mitchell I. J. (1995) Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology 119, 55-65.
10. Carter C. J. (1982) Topographical distribution of possible glutamatergic pathways from the prefrontal cortex to the striatum and substantia nigra of rats. Neuropharmacology 21, 379-383.
11. Double K. L. and Crocker D. (1995) Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc. natn. Acad. Sci. U.S.A. 92, 1669-1673.
12. 1-mediated turning behavior and striatal c-fos expression by the substantia nigra. Synapse 19, 233-240.
13. Fonnum F., Storm-Mathisen J. and Divac I. (1981) Biochemical evidence for glutamate as a neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6, 863-874.
14. Fredriksson A., Gentsch C. and Archer T. (1994) Synergistic interactions between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice. J. neural Transm. 97, 197-209.
15. Gerfen C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15, 133-139.
16. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
17. Greenamyre J. T. (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. neural Transm. 91, 255-269.
18. Herrling P. L. (1985) Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: evidence for its modulation by quisqualate or kainate receptors. Neuroscience 14, 417-426.
19. Imperato A., Scrocco M. G., Bacchi S. and Angelucci L. (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmac. 187, 555-556.
20. Kaur S. and Starr M. S. (1996) Motor effects of lamotrigine in naive and dopamine-depleted mice. Eur. J. Pharmac. 304, 1-6.
21. Kemp J. A. and Leeson P. D. (1993) The glycine site on the NMDA receptor - five years on. Trends pharmac. Sci. 14, 20-25.
22. Klockgether T. and Turski L. (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci. 12, 285-286.
23. Klockgether T. and Turski L. (1990) NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats. Ann. Neurol. 28, 539-546.
24. Klockgether T., Turski L., Honoré T., Zhang Z., Gash D. M., Kurlan R. and Greenamyre J. T. (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30, 717-723.
25. König J. F. R. and Klippel R. A. (1963) The Rat Brain. A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brainstem. Williams and Wilkins, Baltimore.
26. Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., Meguro H., Masaki H., Kumanishi T., Arakawa M. and Mishina M. (1992) Molecular diversity of the NMDA receptor channel. Nature 358, 36-41.
27. Lipton S. A. (1993) Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 16, 527-532.
28. Löscher W., Annies R. and Hönack D. (1991) The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128, 191-194.
29. Löschmann P.-A., Lange K. W., Kunow M., Rettig K.-J., Jähnig P., Honoré T., Turski L., Wachtel H., Jenner P. and Marsden C. D. (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J. neural Transm. 3, 203-213.
30. Luquin M. R., Obeso J. A., Laguna J., Guillén J. and Martinez-Lage J. M. (1993) The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur. J. Pharmac. 235, 297-300.
31. Maj J., Rogoz Z. and Skuza G. (1993) Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice. Pol. J. Pharmac. 45, 349-360.
32. Maj J., Skuza G. and Rogoz Z. (1993) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J. neural Transm. 6, 53-62.
33. McCullough L. D. and Salamone J. D. (1992) Increase in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res. 577, 1-9.
34. Meldrum B. and Leach M. (1994) The mechanisms of action of lamotrigine. Rev. contemp. Pharmacother. 5, 107-114.
35. Mink J. W. and Thach W. T. (1993) Basal ganglia intrinsic circuits and their role in behavior. Curr. Opin. Neurobiol. 3, 950-957.
36. Mitchell I. J., Hughes N., Carroll C. B. and Brotchie J. M. (1995) Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmac. 6, 492-507.
37. 3H]glutamate-binding sites in rat brain. J. Neurosci. 5, 2909-2919.
38. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B. and Seeburg P. H. (1992) Heteromeric NMDA receptors: molecular and functional distribution of subtypes. Science 256, 1217-1221.
39. Moriyoshi K., Masu M., Ishii T., Shigemoto R., Mizuno N. and Nakanishi S. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
40. Nakanishi S. (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597-603.
41. Ossowska K. (1994) The role of excitatory amino acids in experimental models of Parkinson's disease. J. neural Transm. 8, 39-71.
42. Pierce R. and Rebec G. V. (1993) Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via non-dopaminergic mechanisms. J. Neurosci. 13, 4272-4280.
43. Reubi J. and Cuenod M. (1979) Glutamate release in vitro from corticostriatal terminals. Brain Res. 176, 185-188.
44. Riederer P., Lange K. W., Kornhuber J. and Danielczyk W. (1992) Glutamatergic-dopaminergic balance in the brain. Arzneim. Forsch. 42, 265-268.
45. Rinvik E. and Ottersen O. P. (1993) Terminals of subthalamonigral fibres are enriched with glutamate-like immunoreactivity: an electron microscopic, immunogold analysis in the cat. J. Chem. Neuroanat. 6, 19-30.
46. Schmidt W. J. (1986) Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonised by haloperidol and clozapine. Psychopharmacology 90, 123-130.
47. Schmidt W. J., Bubser M. and Hauber W. (1990) Excitatory amino acids and Parkinson's disease. Trends Neurosci. 13, 46-47.
48. Schmidt W. J., Bubser M. and Hauber W. (1992) Behavioural pharmacology of glutamate in the basal ganglia. J. neural Transm., Suppl. 38, 65-89.
49. Sellal F., Hirsch E., Lisovski F., Mutschler V., Collard M. and Marescaux C. (1992) Contralateral disappearance of parkinsonian signs after subthalamic hematoma. Neurology 42, 255-256.
50. Slusher B. S., Rissolo K. C., Jackson P. F. and Pullan L. M. (1994) Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. J. neural Transm. 97, 175-185.
51. Standaert D. G., Testa C. M., Young A. B. and Penney J. B. (1994) Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. comp. Neurol. 343, 1-16.
52. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19, 264-295.
53. Starr M. S. (1995) Antiparkinsonian actions of glutamate antagonists - alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J. neural Transm. 10, 141-185.
54. 2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur. J. Pharmac. 250, 239-246.
55. 2 agonist apomorphine. J. neural Transm. 6, 215-226.
56. 2 dopamine agonists in reserpine-treated mice. Psychopharmacology 114, 469-476.
57. St-Pierre J. A. and Bédard P. J. (1994) Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model. Brain Res. 660, 255-260.
58. Svensson A. and Carlsson M. L. (1992) Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induced pronounced locomotor stimulation. Neuropharmacology 31, 513-518.
59. Tokuno H., Morizumi T., Kudo M. and Nakamura Y. (1988) A morphological evidence for monosynaptic projections from the nucleus pedunculopontinus pars compacta (TPC) to nigrostriatal projection neurons. Neurosci. Lett. 85, 1-4.
60. Wachtel H., Kunow M. and Löschmann P. A. (1992) NBQX (6-nitro-sulfamoyl-benzo-quinoxaline dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci. Lett. 142, 179-182.
61. Williams K., Romano C., Dichter M. A. and Molinoff P. B. (1991) Modulation of the NMDA receptor by polyamines. Life Sci. 48, 469-498.
62. Wüllner U., Kupsch A., Arnold G., Renner P., Scheid C., Scheid R., Oertel W. and Klockgether T. (1992) The competitive NMDA antagonist CGP 40116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology 31, 713-715.
63. + channels in rat hippocampal neurones. Pflügers Arch. 430, 437-446.
64. Yoshida Y., Ono T., Kawano K. and Miyagashi T. (1994) Distinct sites of dopaminergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res. 639, 139-148.